- Home
- PMVP vs TLSA Comparison
PMVP vs TLSA Comparison
Compare PMVP & TLSA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- PMVP
- TLSA
- Stock Information
- Founded
- PMVP 2013
- TLSA 2013
- Country
- PMVP United States
- TLSA United Kingdom
- Employees
- PMVP N/A
- TLSA N/A
- Industry
- PMVP Medicinal Chemicals and Botanical Products
- TLSA Biotechnology: Pharmaceutical Preparations
- Sector
- PMVP Health Care
- TLSA Health Care
- Exchange
- PMVP Nasdaq
- TLSA Nasdaq
- Market Cap
- PMVP 55.1M
- TLSA 175.3M
- IPO Year
- PMVP 2020
- TLSA 2000
- Fundamental
- Price
- PMVP $1.06
- TLSA $1.59
- Analyst Decision
- PMVP Strong Buy
- TLSA
- Analyst Count
- PMVP 1
- TLSA 0
- Target Price
- PMVP $5.00
- TLSA N/A
- AVG Volume (30 Days)
- PMVP 283.2K
- TLSA 261.4K
- Earning Date
- PMVP 08-07-2025
- TLSA 07-11-2025
- Dividend Yield
- PMVP N/A
- TLSA N/A
- EPS Growth
- PMVP N/A
- TLSA N/A
- EPS
- PMVP N/A
- TLSA N/A
- Revenue
- PMVP N/A
- TLSA N/A
- Revenue This Year
- PMVP N/A
- TLSA N/A
- Revenue Next Year
- PMVP N/A
- TLSA N/A
- P/E Ratio
- PMVP N/A
- TLSA N/A
- Revenue Growth
- PMVP N/A
- TLSA N/A
- 52 Week Low
- PMVP $0.81
- TLSA $0.63
- 52 Week High
- PMVP $1.82
- TLSA $1.91
- Technical
- Relative Strength Index (RSI)
- PMVP 52.88
- TLSA 53.42
- Support Level
- PMVP $1.01
- TLSA $1.54
- Resistance Level
- PMVP $1.12
- TLSA $1.81
- Average True Range (ATR)
- PMVP 0.08
- TLSA 0.12
- MACD
- PMVP -0.00
- TLSA 0.01
- Stochastic Oscillator
- PMVP 23.26
- TLSA 50.00
About PMVP PMV Pharmaceuticals Inc.
PMV Pharmaceuticals Inc is a precision oncology company. The company is engaged in the research and development of small molecule, tumor-agnostic therapies targeting p53 mutations, which can eliminate cancer cells. Its pipeline rezatapopt PYNNACLE, rezatapopt and azacitidine, rezatapopt (PC14586), and PMV-586-101.
About TLSA Tiziana Life Sciences Ltd.
Tiziana Life Sciences Ltd is a clinical-stage biotechnology company that specializes in the developing transformative therapies for neurodegenerative and lung diseases. Its clinical pipeline includes drug assets for Secondary Progressive Multiple Sclerosis, ALS. Alzheimer's, Crohn's Disease and KRAS+ NSCLC. Tiziana is led by a team of qualified executives with extensive drug development and commercialization experience.